Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
Last trade$57.56
Day change-$3.01 (-4.97%)
Day range$56.83 – $60.74
Volume960,968
Market cap$2.96B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.96B
Price / earnings
—
Price / book
-40.03×
Price / sales
—
EV / sales
—
EV / EBITDA
-14.57×
Profitability
Earnings per share
-$5.23
Return on assets
-35.22%
Return on equity
345.78%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-10.18×
Current ratio
14.62×
Quick ratio
14.59×
Cash ratio
3.86×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$213.48M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CELC, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$39.8M
$35.04M
$17.44M
$11.57M
$12.42M
$7.59M
$6.37M
$2.96M
Research and development
$37.52M
$31.08M
$33.06M
$37.63M
$30.43M
$36.42M
$29.76M
$33.47M
Total operating expenses
$77.32M
$66.12M
$50.51M
$49.2M
$42.85M
$44.01M
$36.13M
$36.43M
Operating income
-$77.32M
-$66.12M
-$50.51M
-$49.2M
-$42.85M
-$44.01M
-$36.13M
-$36.43M
Interest expense
-$2.69M
-$5.42M
-$6.09M
-$6.17M
-$4.6M
-$3.2M
-$3.18M
-$3.28M
Income before taxes
-$73.34M
-$78.86M
-$52.84M
-$50.97M
-$43.8M
-$45.27M
-$37M
-$36.65M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$73.34M
-$78.86M
-$52.84M
-$50.97M
-$43.8M
-$45.27M
-$37M
-$36.65M
Net income attributable to common shareholders
-$73.34M
-$78.86M
-$52.84M
-$50.97M
-$43.8M
-$45.27M
-$37M
-$36.65M
EBITDA
-$77.26M
-$66.06M
-$50.46M
-$49.15M
-$42.81M
-$43.97M
-$36.1M
-$36.4M
Basic earnings per share
-$1.33
-$1.44
-$0.97
-$0.97
-$0.92
-$1.04
-$0.86
-$0.85
Diluted earnings per share
-$1.33
-$1.44
-$0.97
-$0.97
-$0.92
-$1.04
-$0.86
-$0.85
Recent news
Company coverage with links to the original publishers.
Celcuity announced updated subgroup analyses from the Phase 3 VIKTORIA-1 study showing that gedatolisib triplet and doublet regimens significantly improved median progression-free survival compared to alpelisib plus fulvestrant in HR+/HER2- advanced breast cancer patients with PIK3CA mutations. The gedatolisib triplet achieved 21.5 months median PFS in patients without liver metastases versus 9.1 months for alpelisib, with lower discontinuation rates due to adverse events (5% vs 19%).
Zacks has added three stocks to its Strong Sell list: adidas AG with a 5.1% downward earnings revision, Celcuity Inc. with a 15.3% downward revision, and Collective Mining Ltd. with a 31.8% downward earnings revision over the last 60 days.
Celcuity stock gained 2.8% on Wednesday as the biotech company launched its first FDA-approved drug, Revtorpyk, for HR+/HER2 breast cancer treatment. The company also introduced support services for patients and physicians. The stock outperformed the broader market, which saw the S&P 500 decline 0.3%.
Law firm Kessler Topaz Meltzer & Check is investigating Celcuity Inc. for potential securities law violations following the company's announcement of a delayed drug launch for its FDA-approved breast cancer therapy Revtorpyk. The delayed launch timeline, announced on July 14, 2026, fell short of analyst expectations and triggered a 17% stock price decline. The firm is encouraging investors who suffered losses to contact them regarding potential legal rights.
Law firm Bragar Eagel & Squire is investigating Celcuity Inc. for potential securities violations following the company's announcement of FDA approval for breast cancer therapy Revtorpyk with a delayed commercial launch in late Q3 2026. The delayed timeline, contrary to analyst expectations, triggered a 17.6% stock price decline on July 15, 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.